Levera XR 1000 Tablet contains Levetiracetam 1000 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma concentrations. Levera XR is typically prescribed as adjunctive therapy in adults and pediatric patients aged 16 years and older. It is important to initiate treatment at the recommended dose and titrate gradually to minimize adverse effects, which may include dizziness, somnolence, headache, and behavioral symptoms such as irritability or mood changes. Caution is advised in patients with renal impairment, as dose adjustments may be necessary. Levera XR should be used under strict medical supervision, with regular monitoring of seizure control and potential side effects. Abrupt discontinuation is discouraged due to the risk of increased seizure frequency. This medication is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients. Always consult a healthcare professional before initiating or modifying therapy with Levera XR 1000 Tablet.